Back

A PARP2-specific active site alpha-helix melts to permit DNA damage-induced enzymatic activation

Smith-Pillet, E. S.; Billur, R.; Langelier, M.-F.; Talele, T. T.; Pascal, J. M.; Black, B. E.

2024-05-20 biochemistry
10.1101/2024.05.20.594972 bioRxiv
Show abstract

PARP1 and PARP2 recognize DNA breaks immediately upon their formation, generate a burst of local PARylation to signal their location, and are co-targeted by all current FDA-approved forms of PARP inhibitors (PARPi) used in the cancer clinic. Recent evidence indicates that the same PARPi molecules impact PARP2 differently from PARP1, raising the possibility that allosteric activation may also differ. We find that unlike for PARP1, destabilization of the autoinhibitory domain of PARP2 is insufficient for DNA damage-induced catalytic activation. Rather, PARP2 activation requires further unfolding of an active site -helix absent in PARP1. Only one clinical PARPi, Olaparib, stabilizes the PARP2 active site -helix, representing a structural feature with the potential to discriminate small molecule inhibitors. Collectively, our findings reveal unanticipated differences in local structure and changes in activation-coupled backbone dynamics between PARP1 and PARP2.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.